Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy.
Baumann KH, du Bois A, Meier W, Rau J, Wimberger P, Sehouli J, Kurzeder C, Hilpert F, Hasenburg A, Canzler U, Hanker LC, Hillemanns P, Richter B, Wollschlaeger K, Dewitz T, Bauerschlag D, Wagner U. Baumann KH, et al. Among authors: bauerschlag d. Ann Oncol. 2012 Sep;23(9):2265-2271. doi: 10.1093/annonc/mds003. Epub 2012 Feb 29. Ann Oncol. 2012. PMID: 22377563 Free article. Clinical Trial.
Fluorescence in situ hybridization test for detection of endometrial carcinoma cells by non-invasive vaginal swab.
Weimer J, Hüttmann M, Nusilati A, Andreas S, Röseler J, Tribian N, Rogmans C, Stope MB, Dahl E, Mustea A, Stickeler E, Hedemann N, Flörkemeier I, Tiemann K, Magadeeva S, Dempfle A, Arnold N, Maass N, Bauerschlag D. Weimer J, et al. Among authors: bauerschlag d. J Cell Mol Med. 2023 Feb;27(3):379-391. doi: 10.1111/jcmm.17658. Epub 2023 Jan 10. J Cell Mol Med. 2023. PMID: 36625073 Free PMC article.
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, Bauknecht T, Park TW, Jonat W, Jacobsen A, Sehouli J, Luttges J, Krajewski M, Krajewski S, Reed JC, Arnold N, Hampton GM. Meinhold-Heerlein I, et al. Among authors: bauerschlag d. Oncogene. 2005 Feb 3;24(6):1053-65. doi: 10.1038/sj.onc.1208298. Oncogene. 2005. PMID: 15558012
An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.
Meinhold-Heerlein I, Bauerschlag D, Zhou Y, Sapinoso LM, Ching K, Frierson H Jr, Bräutigam K, Sehouli J, Stickeler E, Könsgen D, Hilpert F, von Kaisenberg CS, Pfisterer J, Bauknecht T, Jonat W, Arnold N, Hampton GM. Meinhold-Heerlein I, et al. Among authors: bauerschlag d. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):458-66. doi: 10.1158/1078-0432.CCR-06-0691. Clin Cancer Res. 2007. PMID: 17255266
Anti-idiotypic antibody abagovomab in advanced ovarian cancer.
Bauerschlag DO, Schem C, Baumann K, Harter P, Hilpert F, Wagner U, du Bois A, Pfisterer J. Bauerschlag DO, et al. Future Oncol. 2008 Dec;4(6):769-73. doi: 10.2217/14796694.4.6.769. Future Oncol. 2008. PMID: 19086842 Review.
109 results